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ABSTRACT 
Exercise-induced bronchoconstriction (EIB) describes the post exercise phenomenon of acute 
airway narrowing in association with physical activity. A high prevalence of EIB is reported 
in both athletic and recreationally active populations. Without treatment, EIB has the 
potential to impact upon both health and performance. It is now acknowledged that clinical 
assessment alone is insufficient as a sole means of diagnosing airway dysfunction due to the 
poor predictive value of symptoms. Furthermore, a broad differential diagnosis has been 
established for EIB, prompting the requirement of objective evidence of airway narrowing to 
secure an accurate diagnosis. This article provides an appraisal of recent advances in 
available methodologies, with the principle aim of optimising diagnostic assessment, 
treatment and overall clinical care.   
  
 
 
 
 
 
 
 
 
Key words: Airway dysfunction, airway-hyperresponsiveness, asthma, athletes, diagnosis, 
exercise-induced bronchoconstriction.  
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“If from running, gymnastic exercises, or any other work, the breathing becomes difficult, it 
is called Asthma” Aretaeus (81–138 AD) [1].  
 
INTRODUCTION  
Respiratory symptoms in association with exercise are reported frequently in both elite 
athletic and recreationally active populations. However, differentiation between a ‘normal’ 
physiologically appropriate and ‘abnormal’ pathophysiological response of the cardio-
respiratory system is complex, presenting a potential for misdiagnosis [2,3].  
The most frequently encountered chronic medical condition in elite athletes is airway 
dysfunction [4]. Depending on the population studied and the diagnostic methodology 
employed, the estimated prevalence varies significantly. For instance, the prevalence in 
Olympians has been estimated at approximately 8% [4], whereas in high risk populations (i.e. 
swimmers and cold-air athletes) the estimate is much greater (25-75%) [5-7]. In contrast, the 
prevalence of airway dysfunction in recreationally active individuals has recently been 
identified at >13% [8]. Consequently, diagnostic accuracy in clinical practice is of 
fundamental importance to ensure the appropriate application of effective treatment.  
Airway dysfunction is a term used to describe the entities of exercise-induced 
bronchoconstriction (EIB), exercise-induced asthma (EIA), airway hyper-responsiveness 
(AHR) and/or asthma [7]. Whilst often used interchangeably with EIA, EIB is the preferred 
terminology given exercise triggers bronchoconstriction rather than inducing the clinical 
syndrome of asthma [9]. Specifically, EIB describes the post exercise phenomenon of acute 
airway narrowing in association with physical activity [5,10]. Clinical characteristics of EIB 
often include dyspnoea, increased perceived effort of breathing, chest tightness, wheezing, 
excessive sputum production and/or cough. In addition, individuals with the aforementioned 
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symptoms may also report a reduction in physical performance and/or earlier onset of fatigue 
following a strenuous bout of exercise [3].  
The diagnosis of EIB in athletes has presented difficulties in the past, predominately because 
baseline spirometry possesses poor predictive value [11] and primary care physicians rely 
heavily on self-report respiratory symptoms. However, it is now established that a symptom-
based approach to diagnosis is imprecise as symptoms correlate poorly with objective 
evidence of airway narrowing [2,12].  As such, it is now recognised that an accurate 
diagnosis of EIB should be established through changes in lung function following a 
provocative stimulus to the distal airways, rather than on the basis of clinical features alone 
[10]. Whilst the International Olympic Committee-Medical Commission (IOC-MC) favour 
eucapnic voluntary hyperpnoea (EVH) as the ‘gold-standard’ bronchoprovocation challenge 
for EIB in athletes [13], a number of supplementary tests are currently available, with 
developments in diagnostic methods an active area of research.  
The aim of this review was therefore to appraise recent developments in available diagnostic 
methodology for EIB in athletes, with the purpose of optimising diagnostic accuracy, 
treatment and clinical care in both athletic and recreationally active populations. Throughout 
the evidence presented is based on a narrative non-systematic review. Publications in peer-
reviewed literature until November 2013 were reviewed using the following terms ‘exercise-
induced asthma or bronchoconstriction’, ‘airway-hyperresponsiveness’, ‘asthma’, ‘airway 
dysfunction’ and ‘diagnosis’, in combination with ‘athletes’. 
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PATHOGENESIS OF EIB  
The last 50 years has consisted of considerable debate surrounding the mechanistic 
development of EIB [14]. Whilst a wealth of research has been conducted [15-18] the 
pathogenesis of EIB remains complex and incompletely understood.  
During intense exercise, ventilation rates may exceed 150L/min resulting in a shift in resting 
breathing pattern from predominately nasal to combined oral and nasal airflow [19]. 
Consequently, the distal airways are exposed to an increase in unconditioned air and potential 
interaction with sport-specific environmental pollutants such as airborne allergens and 
noxious particles [20,21]. The acute development of EIB is thought to precipitate EIB by 
inducing osmotic changes at the distal airway surface whereby desiccation of the airway 
epithelium drives a local osmotic stimulus resulting in cell shrinkage, pro-inflammatory 
mediator release and a shift in cellular ion concentration [15,17,22]. Specifically, evidence 
has highlighted the release of arachidonic acid metabolites such as cysteinyl leukotrienes and 
prostaglandin D2 from mast cells and eosinophils into the airways [23-25]. It has been 
proposed that these respective eicosanoids act as principle mediators resulting in sensory 
nerve activation, smooth muscle contraction [23] and mucus release into the airway lumen 
[26]. See reference [18] for a recent detailed review.  
More recently, a shift in focus towards airway injury has occurred, with recent findings 
indicating that acute exercise hyperpnoea transiently disrupts the airway epithelium [27]. In 
the chronic setting, repeated, sustained periods of exercise hyperpnoea have been associated 
with changes in the contractile properties of smooth muscle analogous to a pathological 
response to injury or insult [28,29]. To date, it is generally accepted that a causal relationship 
exists between repeated exercise hyperpnoea in noxious environments and injury-repair 
cycling of the airway epithelium. Over time this stimulus appears to result in an increase in 
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endobronchial debris, pro-inflammatory cells, cellular inflammatory mediators, airway 
remodelling and overall heightened sensitivity to mediators of bronchoconstriction [7,16,29] 
(Figure 1). 
Furthering our knowledge of the mechanisms underlying the pathogenesis of EIB will 
provide insight into the optimum bronchoprovocation challenges to employ and overall aid 
diagnostic accuracy.  
RESPIRATORY SYMPTOMS  
It is commonplace for primary care physicians to regularly encounter patients reporting 
dyspnoea in association with exercise. Indeed, UK physicians report an encounter with 
symptomatic patients at a rate of approximately once per month [30]. Furthermore, a study of 
700 athletes found that almost 25% report regular symptoms indicative of airway dysfunction 
[31]. Due to the distinguishing characteristics of EIB, physicians often rely solely on self-
report symptoms alone to inform diagnosis. Whilst this may seem intuitive, a wealth of 
literature now opposes this practice, highlighting the fact that symptoms correlate poorly with 
objective evidence of airway narrowing [2], possessing the (in)accuracy of a coin toss [12]. 
For example, studies in athletes implementing a symptom based criteria as the principle 
means of diagnosis generally state prevalence below 20%.  In contrast when objective 
bronchoprovocation challenges are employed the prevalence tends to be above 20% [32,33]. 
Overall, symptoms that are often associated with vigorous exercise are neither sensitive nor 
specific for identifying patients with EIB [34,35].  
Discrepancies in accurate diagnosis and estimated prevalence occur further when considering 
a significant proportion of individuals with airway dysfunction have no previous history of 
symptoms [36,37]. Recent findings from Molphy and colleagues highlight this concern 
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whereby >13% of asymptomatic recreationally trained individuals presented with objective 
evidence of airway narrowing.  
The explanation for the dissociation between symptoms and objective evidence is likely 
multifactorial. A principle concern for physicians encountering patients with exercise-related 
respiratory symptoms is the vast differential diagnosis associated with EIB. For instance, 
cardiac dysfunction, poor physical conditioning or other respiratory disease present 
symptoms during maximal exercise and improve with recovery [3,38]. In addition, accuracy 
of patient self-report is generally non-specific [31] and personality trait, perception of 
symptoms, and expectation of performance likely influence the accuracy of a symptom based 
diagnosis.  
DIAGNOSTIC IMPLICATIONS  
The implications of misdiagnosis can be considered two-fold; firstly and most importantly in 
terms of airway health and secondly regarding athletic performance. 
The impact of airway dysfunction on health spans a broad spectrum, from quality of life to 
morbidity (e.g. exacerbations) and mortality. Whilst longitudinal data suggests no long-term 
consequences of airway dysfunction in former athletes [39] evidence suggests that a high 
proportion of asthma-related deaths occur in elite competitive athletes in association with a 
sporting event [40,41]. Furthermore, misdiagnosis of a condition and failing to implement 
appropriate treatment presents a potential for deterioration. In contrast, when prescribed 
unnecessarily, medication has been associated with degenerative changes in lung function 
and the development of tachyphlaxis following chronic use of beta-2-agonists [42,43].  
Specific to athletic performance, 1993 saw the IOC-MC introduce restrictions in the use of 
asthma medications at international level of competition. This year the World Anti-Doping 
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Agency (WADA) has implemented further changes in their policy for therapeutic use 
exemption (TUE), the process whereby an athlete may use an otherwise prohibited substance 
to treat a medical condition [44]. It is currently acknowledged that clinical assessment is 
insufficient as a sole means of diagnosing airway dysfunction due to the poor predictive value 
of symptoms and the broad differential diagnosis [45]. Thus, the current policy requires 
submission of objective evidence of airway dysfunction following reversibility or 
bronchoprovocation testing before medication can be deemed acceptable.  
DIAGNOSIS OF EIB 
Pre-test instructions  
In order to standardise results and limit the variability in response to bronchoprovocation 
challenges, patients must adhere to a strict criteria prior to testing (Table 1). For surveillance 
purposes in athletes, testing should be performed at the same time of day to minimise diurnal 
variation in airway tone. Furthermore, athletes participating in clinical trials should aim to 
maintain a strict training load between visits.  
Diagnostic guidelines  
The diagnosis of EIB is determined by changes in lung function post exercise. Serial lung 
function measurements post exercise or surrogate challenges are used to determine the 
presence of EIB and quantify the severity of the disorder [10]. The American Thoracic 
Society/European Respiratory Society (ATS/ERS) guidelines currently recommend at least 
two reproducible FEV1 manoeuvres obtained serially following provocation, with the highest 
acceptable value recorded at each interval [46,47]. FEV1 is usually measured at 3,5,10,15 and 
30 minutes post exercise, with a fall in FEV1 ≥10% at two consecutive time points indicative 
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of a positive diagnosis [48]. The severity of EIB can be classified as mild, moderate or severe 
depending on the percent fall in FEV1 and current prescribed medication Table 2. [10]. 
Diagnostic methodology for EIB can be divided into two respective categories; direct and 
indirect bronchoprovocation challenge tests. Direct challenges act directly on specific airway 
smooth muscle receptors to induce constriction independent of airway inflammation [49,50]. 
In contrast, indirect challenges are thought to cause inflammatory cells to release endogenous 
mediators such as leukotrienes, prostaglandins and histamine that provoke airway smooth 
muscle constriction [46,50,51].  
At present the International Olympic Committee (IOC-MC) currently accept a number of 
diagnostic challenges as objective evidence of asthma and EIB. These include bronchodilator 
reversibility testing, eucapnic voluntary hyperpnoea, methacholine challenge testing, 
laboratory and field exercise testing and saline or dry powder mannitol challenges [44,52]. A 
secure diagnosis then depends on confirmatory investigation (proposed assessment algorithm 
is presented in Figure 2). These methods will form the basis of this review; however, a 
comprehensive description for each of the protocols, procedures and techniques employed in 
clinical practice is beyond the scope of this article. For these the reader is referred to the 
relevant ATS/ERS guidelines. In addition, a systematic appraisal of sensitivity and specificity 
previously formulated by Dryden and co-workers [53] using the Grading of 
Recommendations, Assessment, Development and Evaluation (GRADE) approach is 
presented for each respective bronchoprovocation challenge (Table 3).  
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DIRECT BRONCHOPROVOCATION CHALLENGES 
Methacholine vs. Histamine inhalation challenge  
Direct bronchoprovocation challenges such as the methacholine and histamine inhalation 
challenge are the most commonly performed diagnostic tests for AHR [49,54]. Whilst 
methacholine and histamine induce bronchoconstriction at almost equivalent concentrations 
[55,56], methacholine is more commonly employed due to a number of systemic side effects 
associated with histamine including headaches and flushing [47]. In addition, evidence 
suggests that AHR measurements may have greater reproducibility when employing a 
methacholine challenge [57-59]. To date, methacholine is the only direct bronchoprovocation 
challenge recognised by the IOC-MC as appropriate evidence to permit use of inhaled 
medication to treat airway dysfunction in athletes [13]. 
Methacholine inhalation challenge  
Methacholine inhalation challenge is considered a direct challenge as it acts on smooth 
muscle acetylcholine receptors, causing contraction and airway narrowing [60]. The dosing 
protocol of a methacholine challenge consists of either a 2-minute tidal breathing or 
dosimeter method. Specifically, the two minute-tidal breathing method consists of the 
inhalation of aerosol from a jet nebulizer, operated while continually calibrated to an output 
of 0.13ml/min. In contrast, the dosimeter method requires an inhalation of aerosol (9µL per 
actuation) with five deep inspiratory capacity inhalations to total lung capacity, followed by a 
5 second breath hold after each inhalation [49]. Other than the inhalation procedure, the 
recommendations for the respective tests are the same [61]. Administration of a baseline 
control saline diluent begins the test, followed by doubling concentrations of the provocative 
agent from 0.03mg/mL to 16 mg/mL or 32 mg/mL. Intervals of 5 minutes are required 
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between inhalations, with single measures of FEV1 performed at 30 s and 90s post inhalation 
[49]. The percentage fall in FEV1 following the inhalation of methacholine can be calculated 
based on baseline (saline diluent) FEV1. The test is complete when the highest concentration 
of methacholine has been administered, or deemed positive when a 20% fall in FEV1 has 
occurred (PC20, provocative concentration causing a fall in 20% in FEV1). It was previously 
thought that although the volume of aerosol differed between the two methods, the results 
were comparable [62]. However, and of concern, recent evidence has accumulated to suggest 
the tidal-breathing method produces a greater response (lower PC20). This is likely 
multifactorial; firstly, the dose administered is significantly higher with the tidal breathing 
method. Secondly, maximal inspiratory efforts and subsequent breath-holds likely result in a 
degree of bronchodilation in patients with mild AHR [63,64]. Of note, the methods are much 
more comparable in patients with moderate or severe AHR [61,65].  
Airway hyper-responsiveness to pharmacologic agents such as methacholine has been shown 
to differ from hyperresponsiveness to exercise or osmotic agents [47]. Furthermore, unlike 
exercise challenges, methacholine does not infer the presence of inflammatory cells or their 
mediators [51]. Therefore, whilst the arbitrary cut-off points for methacholine results in good 
specificity in diagnosing the clinical syndrome of asthma [49], when considered from an EIB 
perspective, sensitivity and specificity appears inconsistent and imprecise respectively [53]. 
In support of this concept, Holzer and colleagues have previously identified that 
methacholine had a negative predictive value of merely 61% and a sensitivity of 36% for 
identifying EIB in elite athletes in comparison to EVH [66]. A recent systematic appraisal of 
evidence concluded that methacholine is not a valid test to diagnose EIB [53]. Furthermore, a 
positive methacholine test should not be used to infer EIB, and likewise a negative result 
should not exclude EIB [47]. 
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INDIRECT BRONCHOPROVOCATION CHALLENGES 
Exercise challenge tests 
As exercise is a natural provocative stimulus to induce bronchoconstriction in susceptible 
individuals, it seems logical to implement exercise as a diagnostic test.  As such, exercise 
testing was the first indirect bronchoprovocation challenge to be standardised for the 
diagnosis of airway dysfunction [67]. As the mode, duration and intensity of exercise and the 
temperature and water content of the inspired air influence the dehydration/heat transfer of 
the airways [17] both laboratory and sport-specific field tests have been developed [68].  
The reproducibility of exercise testing has previously been established by Anderson and co-
workers [69], with agreement of 76.1% between test results. However, the authors concluded 
that when using exercise to exclude or diagnose EIB, prescribe treatment or implement 
during clinical trials, performing two tests would be advantageous.  
The recommended protocol for the identification of EIB when implementing an exercise 
challenge consists of a rapid increase in exercise intensity over approximately 2-4 minutes to 
achieve a sustained, high level of ventilation. Throughout the challenge, dry, medical grade 
air (<10mg H2O/L) should be inhaled with a nose clip in place (optimising distal airway 
exposer) while running or cycling at a load to sufficiently raise the heart rate to 80-90% of 
predicted maximum (predicted maximum heart rate: 220 (bpm) – age (yr)) [10]. This level of 
exercise should subsequently be maintained for an additional 4-6 minutes, resulting in 
achieving and maintaining VE at approximately 85% maximal voluntary ventilation. Of note, 
when screening highly conditioned or elite level athletes an intensity of approximately 95% 
HRpeak or VO2max test to volitional exhaustion is recommended, thus ensuring a  sufficient 
provocative stimulus [50].  
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Lung function should be assessed at baseline and 3, 5, 10, 15 and 30 minutes post challenge 
in accordance with ATS/ERS guidelines [38,46,47]. The response to an exercise challenge is 
considered positive when there is a fall in FEV1 of ≥10% [48].  
Laboratory vs. Field-based challenges  
Laboratory and field-based exercise challenge tests have been identified to have high 
specificity however possess only moderate sensitivity for EIB [70]. For instance, the 
laboratory challenge test is often performed on a treadmill or cycle ergometer and is limited 
by an inability to achieve the desired workload and thus ventilation rate to induce EIB in 
highly conditioned or elite athletes [71]. In addition, running and cycling possess little 
relevance to the athlete describing symptoms during swimming, football, skiing, skating etc. 
[46]. Finally, the high water content of ambient inspired air limits the drying and desiccation 
of the distal airways to induce bronchoconstriction in susceptible individuals [68].  
Field-based challenges where athletes perform a challenge using their primary mode of 
exercise (i.e. sporting event), are limited by an inability to standardise both the cardiovascular 
workload and key environmental components such as temperature and humidity of inspired 
air [71]. Overall, sensitivity and specificity limitations associated with laboratory and field-
based exercise challenges has resulted in the development of a number of indirect surrogate 
challenges to overcome these problems [72,73].  
Eucapnic voluntary hyperpnoea  
Eucapnic voluntary hyperpnoea is a bronchoprovocation challenge based on the premise that 
increased ventilation rate mimicking high intensity exercise desiccates the distal airways, 
inducing bronchoconstriction in susceptible individuals [50]. Indeed the symptoms indicative 
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of EIB (cough, wheeze, dyspnoea, chest tightness etc.) are often provoked during an EVH 
challenge [71].   
The standardised protocol consists of performing hyperpnoea by inhaling a dry gas mixture 
containing 4.9-5% carbon dioxide, 21% oxygen and nitrogen as the balance. The test is 
performed in ambient conditions at room temperature for a 6-minute period. To minimise the 
likelihood of a false negative test, a ventilation rate equivalent to 30 times baseline FEV1 is 
required [74,75]. As many untrained individuals may fail to achieve this value, 21 times 
baseline FEV1 is the minimum threshold to validate the test [75,76]. As with exercise, a 
≥10% fall in FEV1 from the pre-challenge value following EVH is consistent with a diagnosis 
of EIB [77].  
Eucapnic voluntary hyperpnoea has previously been reported as highly specific for the 
diagnosis of asthma and EIB. Indeed the accuracy of diagnosis for active asthma has been 
shown to be 90% when implementing a 10% fall in FEV1 and 100% when extending the cut-
off value to 15% fall in FEV1 [77]. However, a more recent systematic appraisal of evidence 
[53] suggested that both specificity and sensitivity of an EVH challenge were heterogeneous 
and inconsistent when applied specifically to EIB.  
Although Stadelmann and colleagues have previously observed high repeatability for EVH, 
the time between tests was not defined and evidence of training load maintenance was not 
reported [78]. Accordingly, the short and long-term repeatability of this methodology has yet 
to be fully established.  
In addition, due to the high potency of EVH, a 5-10% fall in FEV1 may well be considered a 
normal airway response. Consequently, debate currently surrounds the treatment of 
asymptomatic athletes with a 10% fall in FEV1. Indeed it remains the opinion of many 
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European researchers studying EIB in athletes (variety of personal communications) that a 
cut-off ≥15% fall in FEV1 should be employed to determine a positive EIB diagnosis. 
Furthermore, when a decline in lung function ‘borderline’ of diagnostic cut-off points is 
observed, further testing should be performed.  
Nonetheless, to date, EVH is recommended as the ‘gold-standard’ challenge by the IOC-MC 
as the most reliable test for the identification of EIB in athletes [13]. However, in athletes 
with severe or poorly controlled asthma, it would be advised to conduct a dry powder 
mannitol or hyperosmolar aerosol test. As these tests are progressive in nature, they are 
therefore unlikely to cause severe bronchoconstriction which may occur following exercise or 
EVH.  
Dry powder mannitol  
Inhaling dry powder mannitol increases the osmolarity of the airway surface liquid causing 
the release of endogenous inflammatory mediators through the same indirect pathway as 
exercise and EVH [79,80]. The protocol for mannitol consists of inhaling increasing doses of 
mannitol delivered via a capsule-based dry powder inhaler [60]. FEV1 is measured in 
duplicate 60 seconds following each administered dose of mannitol (0, 5, 10, 20, 40, 80, 160, 
160, 160 mg). The maximum time for the test should be no longer than 35 minutes for the full 
635mg dose [60]. A positive test result is a 15% fall in FEV1 in comparison to pre-challenge 
FEV1 [60]. Following a systematic appraisal of current evidence from Dryden and co-workers 
[53], the sensitivity and specificity of mannitol has been estimated between 58 to 96% and 65 
to 78% respectively. The authors concluded that whilst such estimates are reasonably 
consistent, they lack precision, overall questioning the reliability of dry powder mannitol as a 
diagnostic test for EIB.  
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Hyperosmolar aerosol 
Similar to mannitol, the hyperosmolar (4.5%) inhaled saline test was developed as a surrogate 
to exercise based on the principle osmotic stimulus of evaporative water loss during exercise 
[81]. The recommended protocol for inhaled saline consists of the patient inhaling the saline 
via tidal breathing from a large volume ultrasonic nebuliser for a period of 30 seconds. FEV1 
is measured in duplicate 60 seconds post exposure. If the reduction is <10% of pre-challenge 
FEV1 then the exposure to the saline is doubled (e.g. 30 sec, 60 sec, 2 min, 4 min, 8 min). If 
the reduction in FEV1 is ≥10% of the pre-challenge, the same dose is repeated. The test is 
terminated when the FEV1 falls by 15% or when the maximum dose of 23 grams has been 
administered in 15.5 minutes [82]. The diagnostic sensitivity and specificity of PD15 to 4.5% 
saline when based on ≥10% FEV1 fall was 53.9% and 84.7% respectively in a cohort of 
children (n = 348) [83].  
ADDITIONAL DIAGNOSTIC TESTS 
Due to the difficulties obtaining an accurate diagnosis of airway dysfunction through specific 
bronchoprovocation challenges, a number of supplementary measurements have been 
developed and employed.  
Atopic status 
As self-report symptoms only provide a supportive role to inform diagnosis, implementing 
screening questionnaires such as the Allergy Questionnaire for Athletes (AQUA) [84] may be 
valuable in providing a structured and objective patient clinical history. Furthermore, 
objective tests such as skin prick testing are often employed in clinical practice to determine 
atopic disposition to common airborne allergens. Determining atopic status is important as 
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the likelihood of an athlete having increased bronchial responsiveness increases to the 
number of positive skin responses [85].  
Impulse oscillometry 
Impulse oscillometry (IOS) provides an alternative method of measuring lung mechanics in 
respiratory disease states. Impulse oscillometry consists of random pressure pulses of 5Hz to 
35Hz (produced by a small loudspeaker in connection with a pneumotach) applied during 
tidal breathing. In contrast to spirometry, IOS is a non-effort dependent test, and therefore has 
application in patients who are unable to deliver a forced expiration (i.e. elderly or paediatric 
populations). Therefore, IOS is advantageous in that results cannot be manipulated by the 
patient [86], nor does it induce respiratory fatigue [87]. In addition, IOS has previously been 
identified to correlate with both FEV1 [88,89] and airway resistance [90,91] as determined by 
spirometry and body plethysmography respectively.  
Specific to EIB, IOS has been shown to be an acceptable measure to supplement spirometry 
following EVH [92]. In support of these findings, Evans and colleagues observed strong 
correlations between spirometry and IOS variables. Furthermore, IOS possessed greater 
sensitivity compared to spirometry when detecting change in airway function following EVH 
and exercise [93,94]. Consequently, IOS may provide a potential adjunct to reliable and 
accurate diagnosis of EIB.  However the utility and clinical relevance of IOS in respiratory 
medicine is widely disputed and the repeatability in this setting has yet to be established.  
Inflammatory biomarkers 
Inflammatory biomarkers such as fractional exhaled nitric oxide (FENO), exhaled breath 
temperature (EBT) and exhaled breath condensate (EBC) provide a potential diagnostic role 
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including predicting and monitoring airway dysfunction [95-97] (see reference [98] for a 
detailed overview).  
Fractional exhaled nitric oxide is regarded as an indirect marker for up-regulation of airway 
inflammation [99]. A recent systematic review by Feitosa and co-workers [100], established 
that overall FENO is a reliable test to determine the presence of EIB. The authors concluded 
that a strong possibility of EIB occurred when a cut-off point is set at >28ppb for children 
under 8 years old and >12ppb for adults, and ruled out with a cut-off point of <20 for children 
between 5-16 years old and <7ppb for adults.   
Exhaled breath condensate measures a number of compounds including biomarkers of 
inflammation (e.g. leukotrienes, prostaglandins, cytokines, adenosine, chemokines and 
interleukins) and oxidative stress (e.g. 8-isoprostanes, H202) [98]. In addition to diagnosis, the 
use of EBC has precedence in monitoring the effectiveness of treatment and also 
understanding the pathogenesis of EIB.  
Exhaled breath temperature may also provide insight into securing a diagnosis of EIB. A 
recent study by Peroni and colleagues [96] demonstrated a mean increase in tidal EBT of 
approximately 0.4°C from baseline following a 6-minute exercise challenge in asthmatic 
children. The increase in EBT correlated with the maximum fall in FEV1 supporting the 
hypothesis that EBT is a composite biomarker that may be used to monitor aspects of airway 
dysfunction i.e. airway remodelling and inflammation.   
Implementing inflammatory biomarker analysis in clinical practice provides additional 
evidence to ensure secure diagnosis and accurate treatment.  To date, FENO is the gold 
standard gas for assessing airway response to exercise hyperpnoea; however EBT and EBC 
likely provide additional beneficial information. Overall, the simplicity, cost, timeframe and 
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non-invasive nature make employing these methodologies attractive to daily clinical practice. 
In addition, the application of biomarker analysis would be of particular relevance for 
surveillance purposes in athletic populations susceptible to the development of EIB (i.e. 
swimmers and cold-air athletes).  
DIFFERENTIAL DIAGNOSIS  
A broad differential diagnosis for EIB exists in elite athletes including anaemia, physical 
deconditioning, cardiac and other pulmonary diseases [101] (see reference [9] for a detailed 
overview). Whilst a thorough clinical history and physical examination in conjunction with 
specific lung function, bronchoprovocation challenges, and cardio-pulmonary exercise testing 
(CPET) can with certainty exclude the majority of respiratory and cardiac related disorders, 
some conditions will require further investigation and specialist tests [9] (Figure 2). A highly 
prevalent differential or mimic of EIB in young athletes is exercise-induced laryngeal 
obstruction (EILO) – ‘an abnormal laryngeal response to exercise’ in which clinical features 
such as dyspnoea and wheezing are generated from the upper airways [9,101,102]. 
Accordingly, symptomatic athletes with a negative bronchoprovocation challenge may 
require nasendoscopic evaluation of their laryngeal movement – recorded continuously 
during exercise [102]. A recent study by Walsted and colleagues observed that from a cohort 
of 88 athletes, approximately one third had evidence of EILO as an explanation for their 
exercise-related respiratory symptoms [102]. However, it is important to highlight that 
although EIB and EILO are separate clinical entities, they may co-exist in the same patient 
[103]. When considering differentiation is particularly difficult when symptoms are 
employed as the primary means of diagnosis, implementing objective testing in clinical 
practice is of paramount importance.  
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SUMMARY   
In conclusion, exercise-induced bronchoconstriction presents with non-specific symptoms 
that make diagnosis based on medical history and physical examination both challenging and 
unreliable. Therefore, objective testing is often required and strongly recommended to 
confirm or refute a diagnosis of EIB. In addition, the importance of careful consideration for 
potential differential diagnosis should not be overlooked.  
The appraisal of current literature supports the use of indirect bronchoprovocation challenges, 
with EVH currently deemed as the optimal challenge by the IOC-MC to secure a diagnosis of 
EIB in athletes. Whilst employing an indirect bronchoprovocation challenge is advised as the 
first course of action, caution is recommended when diagnosing based on a solitary screening 
and a stringent cut-off value of ≥10% fall in FEV1.  Indeed borderline cases may merit follow-
up testing to ensure a correct diagnosis has been established prior to initiating treatment. 
Furthermore, it is important to highlight that regular surveillance of lung function following a 
diagnosis should be implemented (i.e. monitor changes in inflammatory biomarkers) in order 
to effectively modify treatment and optimise clinical care.  
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TABLE FOOTNOTES 
Table 1. Pre-test patient instructions.  
 
Table 2. Severity of EIB based on decline in FEV1 following a bronchoprovocation challenge. 
Definition of abbreviations: EIB; exercise-induced bronchoconstriction; FEV1; forced 
expiratory volume in one second.  
 
Table 3. Summary of sensitivity and specificity for the bronchoprovocation challenges 
currently accepted by the IOC-MC.  
Definition of abbreviations: GRADE; Grading of Recommendations Assessment, 
Development and Evaluation; EIB; exercise-induced bronchoconstriction; FEV1; forced 
expiratory volume in one second.  
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Table 1.  
Confounding factors Patient requirements 
Clothing  Avoid wearing tight, restrictive clothing when performing lung function tests.  
Smoking  Do not smoke for at least 1 hour prior.  
Exercise  Avoid vigorous exercise on the day of testing.  
Diet 
 Avoid eating 2 hours prior to testing.  
 Avoid caffeine on the day of testing. 
 Do not consume alcohol on the day of testing.  
Medication 
 Abstain from anti-histamine medication 24 hours prior to 
testing.  
 Abstain from short-acting beta2 agonists (e.g. salbutamol) 
24 hours prior to testing. 
 Abstain from inhaled corticosteroids 72 hours prior to 
testing.  
Other medical conditions 
 Do not perform lung function testing on patients who 
have any of the following conditions:  
 Recent myocardial infarction/unstable angina 
 Recent abdominal/thoracic/eye surgery 
 Pneumothorax 
 Haemoptysis of unknown cause 
23 
 
Table 2.  
 
 
 
 
Classification of EIB severity Percent decrease in FEV1 
Normal airway response      0% - <10 % 
Mild ≥10% - <25% 
Moderate ≥25% - <50% 
Severe (steroid-naïve patients)  ≥50%  
Severe (steroid-treated patients) ≥30% 
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Diagnostic challenge Diagnostic cut-off point Evidence Sensitivity Specificity               Recommendation 
Direct bronchoprovocation 
Methacholine 
 
≥20%  FEV1 fall [65] 
 
Systematic 
appraisal –  
GRADE  [53] 
Study (n = 15) 
 
0 - 100% 
 
0 - 100% 
 
 A positive or negative test result to 
methacholine does not fully confirm or refute a 
diagnosis of EIB. 
 As methacholine does not infer the presence of 
inflammatory mediators, indirect challenge 
testing should ideally be performed to confirm 
diagnosis i.e. EVH. 
Indirect 
bronchoprovocation 
Exercise challenge test 
 
≥10%  FEV1 fall [104] 
 
Systematic 
appraisal – 
GRADE [53] 
Study (n = 4) 
 
0 - 100% 
 
79 - 100% 
 
 Additional diagnostic tests may be required to 
confirm or refute a diagnosis of EIB.  
 Laboratory: Standardised environmental 
conditions however may be limited by desired 
ventilation rate when screening highly 
conditioned or elite athletes. 
 Field: Allows athletes to perform a challenge 
using their primary mode of exercise, however 
difficult to standardise workload and 
environmental conditions.  
Eucapnic voluntary 
hyperpnea 
≥10%  FEV1 fall [77,104] Systematic 
appraisal - 
GRADE [53] 
Study (n = 7) 
25 - 100% 0 - 74%  Currently recognised by the IOC-MC as the 
‘gold-standard’ bronchoprovocation test. 
 Caution is advised when making a diagnosis 
based on a solitary screening of ≥10% fall in 
FEV1.  Surveillance is recommended.  
Dry powder mannitol ≥15%  FEV1 fall [82] Systematic 
appraisal - 
58 - 96% 65 - 78%  Specialist, expensive equipment.  
 May have precedence over EVH in athletes 
Table 3.  
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GRADE [53] 
Study (n = 3) 
exercising in warm, humid environmental 
conditions. 
 Further research required to understand the 
utility of mannitol as a diagnostic challenge for 
EIB in athletes. 
 Advised when screening athletes with severe or 
poorly controlled asthma.  
Hypertonic saline 4.5% ≥15%  FEV1 fall [82] Epidemiologic 
survey [83] 
Study (n = 1) 
53.9% 84.7%  Specialist, expensive equipment.  
 Further research required to understand the 
utility of hypertonic saline as a diagnostic 
challenge for EIB in athletes. 
 Advised when screening athletes with severe or 
poorly controlled asthma. 
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FIGURE LEGENDS 
Figure 1. Impact of exercise hyperpnoea on airway health in susceptible athletes. 
Reproduced with permission from Price and Hull [105].  
 
Figure 2. Approach to the diagnostic assessment and management of asthma in elite athletes 
with suspected airway dysfunction. Reproduced with permission from Hull et al. [101].  
 
***Permission required before figures are published in Expert Reviews*** 
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